Clinical Trial Goal
To find out if the combination of mogamulizumab and ECP is safe and works well to treat mycosis fungoides or Sezary syndrome
You may be able to join this trial if you:
- Are 18 years old or older
- Have mycosis fungoides or Sezary syndrome
- Have not had mogamulizumab
- Have not had an autologous (your own cells) blood or marrow transplant (BMT)
- Have not had an allogeneic (cells from a donor) BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ECP is a procedure in which white blood cells are collected from your body and exposed to ultraviolet A (UVA) light before being returned to you.
Mogamulizumab is a monoclonal antibody that targets CCR4 on certain cells.
You’ll get treatment in cycles that last a month. In each cycle, you'll get:
Mogamulizumab is a monoclonal antibody that targets CCR4 on certain cells.
You’ll get treatment in cycles that last a month. In each cycle, you'll get:
- ECP – Given 4 times
- Mogamulizumab – Given as intravenous (IV) infusions 2 or 4 times
You may continue treatment for up to 1 year. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year after treatment.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this combination to treat mycosis fungoides or Sezary syndrome is new and unproven.
Locations
Mayo ClinicRECRUITING
Scottsdale, Arizona
Aaron Mangold, MD, 480-301-8484, Mangold.Aaron@mayo.edu
City of Hope Medical CenterRECRUITING
Duarte, California
Christiane R. Querfeld, 626-218-5822, cquerfeld@coh.org
Winship Cancer Institute of Emory UniversityRECRUITING
Atlanta, Georgia
Pamela Allen, MD, 404-778-6195, pamela.b.allen@emory.edu
Sponsors
collaborator: National Cancer Institute (NCI), lead: City of Hope Medical Center
